Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 12, 2015, Pages 1180-1193

  Chilton, R ^a   Tikkanen, I ^b   Cannon, C P ^c   Crowe, S ^d   Woerle, H J ^d   Broedl, U C ^d   Johansen, Odd Erik ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Boehringer Ingelheim Norway KS   (Norway)

Author keywords

Cardiovascular disease; Phase III study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASCULAR RESISTANCE; ARTERIOSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; ARTERIOSCLEROSIS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; HEART RATE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 84945455839     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12572     Document Type: Article

References (45)

1. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015; 38(Suppl. 1): S1-93.
2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR etal. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
3. [ESC/EASD] Task Force on Diabetes, Pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD), Rydén L, Grant PJ, Anker SD etal. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab Vasc Dis Res 2014; 11: 133-173.
4. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108: 1527-1532.
5. Hsueh WA, Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13: 224-237.
6. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013; 13: 13.
7. Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am 2014; 43: 103-122.
8. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527-539.
9. Wagenseil JE, Mecham RP. Elastin in large artery stiffness and hypertension. J Cardiovasc Transl Res 2012; 5: 264-273.
10. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327.
11. Nilsson PM, Boutouyrie P, Cunha P etal. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens 2013; 31: 1517-1526.
12. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systematic meta-analysis. Heart Fail Rev 2015; 20: 291-303.
13. Jung CH, Jung SH, Kim KJ etal. Differential associations of central and brachial blood pressure with carotid atherosclerosis and microvascular complications in patients with type 2 diabetes. BMC Cardiovasc Disord 2014; 14: 23.
14. Nilsson PM, Cederholm J, Eeg-Olofsson K etal. Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). Diabetes Metab 2009; 35: 439-446.
15. Yu D, Simmons D. Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with type 2 diabetes: a population-based case-control study. Diabet Med 2015; 32: 1201-1206.
16. Kodama S, Horikawa C, Fujihara K etal. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 2014; 113: 1058-1065.
17. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-1871.
18. Dolan E, Li Y, Thijs L etal. Ambulatory arterial stiffness index: rationale and methodology. Blood Press Monit 2006; 11: 103-105.
19. Kollias A, Stergiou GS, Dolan E, O'Brien E. Ambulatory arterial stiffness index: a systematic review and meta-analysis. Atherosclerosis 2012; 224: 291-301.
20. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens 1999; 12: 50S-55S.
21. Inoue R, Ohkubo T, Kikuya M etal. Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study. Am J Hypertens 2012; 25: 568-575.
22. Grempler R, Thomas L, Eckhardt M etal. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
23. Roden M, Weng J, Eilbracht J etal. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-219.
24. Häring HU, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659.
25. Häring HU, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
26. Kovacs CS, Seshiah V, Swallow R etal. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-158.
27. Tikkanen I, Narko K, Zeller C etal. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-428.
28. Nishimura R, Tanaka Y, Koiwai K etal. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015; 14: 11.
29. Cherney DZ, Perkins BA, Soleymanlou N etal. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
30. Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl 1999; 17: S29-36.
31. Younis F, Hollander K, Mayoux E etal. Effect of prophylactic treatment with empagliflozin on cardiac function and diabetes in CRDH rats. Diabetes 2014; 63(Suppl. 1): A273 [1056-P].
32. Jordan J, Tank J, Heusser K etal. Empagliflozin (EMPA) has no discernable effect on muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes (T2DM) despite reductions in blood pressure (BP) and weight. Diabetes 2014; 63: A265 (Suppl. 1).
33. Baker WL, Smyth LR, Riche DM etal. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275.
34. Dengo AL, Dennis EA, Orr JS etal. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension 2010; 55: 855-861.
35. Ferreira MT, Leite NC, Cardoso CRL, Salles GF. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio de Janeiro type 2 diabetes cohort study. Diabetes Care 2015; 38: 897-904.
36. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 2002; 40: 804-809.
37. Oelze M, Kröller-Schön S, Welschof P etal. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 2014; 9: e112394.
38. Lin B, Koibuchi N, Hasegawa Y etal. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 2014; 13: 148.
39. AstraZeneca Pharmaceuticals LLP. Farxiga™ (dapagliflozin) US prescribing information. 2014.
40. ® (empagliflozin) US prescribing information. 2014.
41. Janssen Pharmaceticals Inc. Invokana™ (canagliflozin) US prescribing information. 2014.
42. Frishman WH. Increased vascular compliance/decreased cardiovascular risk: what the studies tell us. Heart Dis 2000; 2: 384-388.
43. Cameron JD, Asmar R, Struijker-Boudier H etal. Current and future initiatives for vascular health management in clinical practice. Vasc Health Risk Manag 2013; 9: 255-264.
44. Inzucchi SE, Zinman B, Wanner C etal. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12: 90-100.
45. Zinman B, Inzucchi SE, Lachin JM etal. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014; 13: 102.